Skeletal formula (top) Ball-and-stick model (bottom)
|Trade names||Benzac, Clearasil, PanOxyl, others|
|AHFS/Drugs.com||Multum Consumer Information|
|Synonyms||benzoperoxide, dibenzoyl peroxide (DBPO)|
|E number||E928 (glazing agents, ...)|
|Chemical and physical data|
|Molar mass||242.23 g·mol−1|
|3D model (Jmol)|
|Melting point||103 to 105 °C (217 to 221 °F) decomposes|
|Solubility in water||poor mg/mL (20 °C)|
|See also: data page|
Benzoyl peroxide (BPO) is a medication and industrial chemical. As a medication it is used to treat mild to moderate acne. For more severe cases it may be used together with other treatments. Some versions come mixed with antibiotics such as clindamycin. Other uses include bleaching flour, hair bleaching, teeth whitening, and textile bleaching. It is also used in the plastic industry.
Common side effects are skin irritation, dryness, or peeling. Use in pregnancy is of unclear safety. Benzoyl peroxide is in the peroxide family of chemicals. In acne it works by killing bacteria.
Benzoyl peroxide was first made in 1905 and came into medical use in the 1930s. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Benzoyl peroxide is avaliable as a generic medication and over the counter. In the United Kingdom 150 ml of a 10% solution costs the NHS about 4.00 pounds. In the United States a month of treatment costs less than 25 USD.
Benzoyl peroxide is effective for reducing the number and severity of acne lesions. BPO has a bactericidal effect on Propionibacterium acnes bacteria associated with acne and does not induce antibiotic resistance. It may be combined with salicylic acid, sulfur, erythromycin or clindamycin (antibiotics), or adapalene (a synthetic retinoid). Two common combination drugs include benzoyl peroxide/clindamycin and adapalene/benzoyl peroxide, an unusual formulation considering most retinoids are deactivated by peroxides. Combination products such as benzoyl peroxide/clindamycin and benzoyl peroxide/salicylic acid appear to be slightly more effective than benzoyl peroxide alone for the treatment of acne lesions.
Benzoyl peroxide for acne treatment is typically applied to the affected areas in gel, cream, or liquid, in concentrations of 2.5% increasing through 5.0%, and up to 10%. No strong evidence supports the idea that higher concentrations of benzoyl peroxide are more effective than lower concentrations.
Benzoyl peroxide commonly causes initial dryness and sometimes irritation, although the skin develops tolerance after a week or so. A small percentage of people are much more sensitive to it and liable to suffer burning, itching, crusting, and possibly swelling. It is sensible to apply the lowest concentration and build up as appropriate. Once tolerance is achieved, increasing the quantity or concentration and gaining tolerance at a higher level may give better subsequent acne clearance. Irritation can also be reduced by avoiding harsh facial cleansers and wearing sunscreen prior to sun exposure.
Other common uses for benzoyl peroxide include
- Bleaching hair
- Tooth whitening systems
- The preparation of bleached flour
- As a convient oxidant in organic chemistry
- An initiator and catalyst for polyester thermoset resins, as an alternative to the much more hazardous methyl ethyl ketone peroxide.
- A hardener in order to start the polymerization process in resins. For instance, PMMA resins can be polymerized with benzoyl peroxide.
- Removing ink and dye stains on vinyl dolls and other playscale figures.
In the U.S., the typical concentration for benzoyl peroxide is 2.5% to 10% for both prescription and over-the-counter drug preparations that are used in treatment for acne. Higher concentrations are used for hair bleach and teeth whitening. Benzoyl peroxide, like most peroxides, is a powerful bleaching agent. Contact with fabrics or hair can cause permanent color dampening almost immediately. Even secondary contact can cause bleaching; for example, contact with a towel that has been used to wash off benzoyl peroxide-containing hygiene products.
Concentrated benzoyl peroxide is potentially explosive like other organic peroxides, and can cause fires without external ignition. The hazard is acute for the pure material, so the compound is generally used as a solution or a paste. For example, cosmetics contain only a small percent of benzoyl peroxide and pose no explosion risk.
The carcinogenic potential of benzoyl peroxide has been investigated. A 1981 study published in the journal Science found that although benzoyl peroxide is not a carcinogen, it does promote cell growth when applied to an initiated tumor. The study concluded, "caution should be recommended in the use of this and other free radical-generating compounds".
In a 1977 study using a human maximization test, 76% of subjects acquired a contact sensitization to benzoyl peroxide. Formulations of 5% and 10% were used.
The U.S. National Institute for Occupational Safety and Health has developed criteria for a recommended standard for occupational exposure to benzoyl peroxide.
It consists of two benzoyl groups bridged by a peroxide link. Its structural formula is (C6H5CO)2O2. It is one of the most important organic peroxides in terms of applications and the scale of its production.
Benzoyl peroxide was the first organic peroxide prepared by intentional synthesis. It was prepared by treating benzoyl chloride with barium peroxide, a reaction that probably follows this equation:
- 2 C6H5C(O)Cl + BaO2 → (C6H5CO)2O2 + BaCl2
- 2 C6H5COCl + H2O2 + 2 NaOH → (C6H5CO)2O2 + 2 NaCl + 2 H2O
- (C6H5CO)2O2 → 2 C
The symbol • indicates that the products are radicals; i.e., they contain at least one unpaired electron. Such species are highly reactive. The homolysis is usually induced by heating. The half-life of benzoyl peroxide is one hour at 92 °C. At 131 °C, the half-life is one minute.
- Stellman, Jeanne Mager (1998). Encyclopaedia of Occupational Health and Safety: Guides, indexes, directory. International Labour Organization. p. 104. ISBN 9789221098171.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 307-308. ISBN 9789241547659. Retrieved 8 January 2017.
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 820. ISBN 9780857111562.
- Plewig, G.; Kligman, A. M. (2012). ACNE and ROSACEA (3 ed.). Springer Science & Business Media. p. 613. ISBN 9783642597152.
- Pommerville, Glendale Community College Jeffrey C.; Pommerville, Jeffrey (2012). Alcamo's Fundamentals of Microbiology: Body Systems. Jones & Bartlett Publishers. p. 214. ISBN 9781449605957.
- Braun-Falco, Otto; Plewig, Gerd; Wolff, Helmut Heinrich; Burgdorf, Walter (2012). Dermatology (2 ed.). Springer Science & Business Media. p. 1039. ISBN 9783642979316.
- Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 173. ISBN 9781284057560.
- "Benzoyl peroxide topical Use During Pregnancy | Drugs.com". www.drugs.com. Retrieved 13 January 2017.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- Klenk, Herbert; Götz, Peter H.; Siegmeier, Rainer; Mayr, Wilfried (2005), "Peroxy Compounds, Organic", Ullmann's Encyclopedia of Industrial Chemistry, Weinheim: Wiley-VCH, doi:10.1002/14356007.a19_199
- Simonart, T. (December 2012). "Newer approaches to the treatment of acne vulgaris". Am. J. Clin. Dermatol. 13 (6): 357–64. doi:10.2165/11632500-000000000-00000. PMID 22920095.
- Seidler, E. M.; Kimball, A. B. (July 2010). "Meta-analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne". J. Am. Acad. Dermatol. 63 (1): 52–62. doi:10.1016/j.jaad.2009.07.052. PMID 20488582.
- "Benzoyl peroxide". Mayo Clinic. January 1, 2016.
- Alldredge, Brian K., ed. (2013). Applied Therapeutics: The Clinical Use of Drugs (10th ed.). Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 949. ISBN 978-1609137137.
- "Error - Evonik Industries AG" (PDF).
- Stevens, Cynthia. "Oxy10 for vinyl stains. Benzoyl Peroxide removes stain from Vinyl. Restore Dolls". Prilly Charmin Dolls. Retrieved 9 February 2015.
- Bojar, R. A.; Cunliffe, William; Holland, K. T. (1995), "The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora", Br. J. Dermatol., 132 (2): 204–8, doi:10.1111/j.1365-2133.1995.tb05014.x, PMID 7888356
- Cartwright, Hugh (17 March 2005). "Chemical Safety Data: Benzoyl peroxide". Oxford University. Retrieved 13 August 2011.
- Slaga, TJ; Klein-Szanto, AJ; Triplett, LL; Yotti, LP; Trosko, KE (2012-05-24). "Skin tumor-promoting activity of benzoyl peroxide, a widely used free radical-generating compound". Science. 213 (4511): 1023–5. Bibcode:1981Sci...213.1023S. doi:10.1126/science.6791284. PMID 6791284.
- Leyden, James J.; Kligman, Albert M. (1977), "Contact sensitization to benzoyl peroxide", Contact Dermatitis, 3 (5): 273–75, doi:10.1111/j.1600-0536.1977.tb03674.x
- "Criteria for a Recommended Standard: Occupational Exposure to Benzoyl Peroxide (77-166)". CDC - NIOSH Publications and Products. June 6, 2014. Retrieved 2016-07-15.
- Brodie, B. C. (1858), "Ueber die Bildung der Hyperoxyde organischer Säureradicale" [On the Formation of the Peroxides of Organic Acid Radicals], Justus Liebigs Ann. Chem., 108: 79–83, doi:10.1002/jlac.18581080117
- Li, Hui, III (1998). "Chapter 2". Synthesis, Characterization and Properties of Vinyl Ester Matrix Resins (PDF) (Ph.D.). University of Vermont.
- Benzoyl peroxide (PDF), SIDS Initial Assessment Report, Geneva: United Nations Environment Programme, April 2004
- International Chemical Safety Card 0225
- "NIOSH Pocket Guide to Chemical Hazards #0052". National Institute for Occupational Safety and Health (NIOSH).
- SIDS Initial Assessment Report from the Organisation for Economic Co-operation and Development (OECD)
- "Benzoyl peroxide", Re-evaluation of Some Organic Chemicals, Hydrazine and Hydrogen Peroxide (PDF), IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 71, Lyon: International Agency for Research on Cancer, 1999, pp. 345–58, ISBN 92-832-1271-1.